Characteristics of Dupilumab-Treated Patients with Atopic Dermatitis Over Time: A Cross-Sectional Assessment of Potential Channeling Bias upon Pediatric Label Extension

Category	Detail
Condition	Atopic Dermatitis
Key Mechanisms	Dupilumab is a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling, key drivers of Type 2 inflammation.
Target Population	Patients with moderate-to-severe atopic dermatitis, including pediatric populations.
Care Setting	Real-world observational studies and pharmacovigilance.

Dupilumab was initially approved for adults in March 2017, with subsequent pediatric label expansions in March 2019, May 2020, and June 2022.
Patients initiating dupilumab at initial approval had higher disease burden compared to those starting after pediatric label extensions.
Channeling bias may affect the interpretation of safety and effectiveness outcomes in real-world studies.
Distinct atopic comorbidity profiles complicate the assessment of channeling bias in pediatric populations.
Understanding baseline risk profiles of new dupilumab users is critical for pharmacovigilance.

Consider the severity of atopic dermatitis and comorbidities when prescribing dupilumab.

Monitor for adverse outcomes and effectiveness in patients initiating dupilumab, especially in newly licensed pediatric groups.

Channeling bias may lead to confounding in observational studies, affecting the interpretation of treatment outcomes.

Patients aged ≥ 1 year with a diagnosis of atopic dermatitis.

Dupilumab is prescribed based on disease severity and patient comorbidities, with evolving treatment patterns observed over time.

Evaluate patient characteristics prior to initiating dupilumab to assess disease burden.
Consider the timing of dupilumab initiation in relation to FDA approvals when conducting observational studies.
Utilize comprehensive patient data to inform treatment decisions and monitor outcomes.

Clinical Scorecard: Longitudinal Analysis of Patient Characteristics in Dupilumab Treatment for Atopic Dermatitis: Investigating Channeling Bias Following Pediatric Label Expansion